Filtered By:
Source: Atherosclerosis
Condition: Heart Failure
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 212 results found since Jan 2013.
Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study
CONCLUSIONS: Renin suppression and aldosterone excess, consistent with primary aldosteronism pathophysiology, were associated with cardiac structural and functional alterations and may represent an early target for mitigation of fibrosis with mineralocorticoid receptor antagonists.PMID:35582954 | DOI:10.1161/HYPERTENSIONAHA.122.19134
Source: Atherosclerosis - May 18, 2022 Category: Cardiology Authors: Jenifer M Brown Magnus O Wijkman Brian L Claggett Amil M Shah Christie M Ballantyne Josef Coresh Morgan E Grams Zhiying Wang Bing Yu Eric Boerwinkle Anand Vaidya Scott D Solomon Source Type: research
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
Med (N Y). 2021 Nov 12;2(11):1203-1230. doi: 10.1016/j.medj.2021.10.004.ABSTRACTCardiovascular and renal outcome trials (CVOTs) for glucagon-like-peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) highlight new options for people with and without type 2 diabetes (T2D). Drugs within these classes reduce rates of major adverse cardiovascular events (MACE), with SGLT2i simultaneously attenuating decline in kidney function. SGLT2i reduce rates of heart failure in people with and without T2D, whereas GLP1RA lower rates of myocardial infarction and stroke in people with T2D with or withou...
Source: Atherosclerosis - May 19, 2022 Category: Cardiology Authors: David Z I Cherney Jacob A Udell Daniel J Drucker Source Type: research
Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective
We present Lp(a) threshold values that may be clinically relevant and identify other cardiovascular risk factors that may modulate the absolute risk of CVD in individuals with high Lp(a) levels. Finally, we identify key clinical and research questions that require further investigation to eventually and optimally reduce CVD risk in patients with high Lp(a) levels.PMID:35606078 | DOI:10.1016/j.atherosclerosis.2022.04.015
Source: Atherosclerosis - May 23, 2022 Category: Cardiology Authors: Benoit J Arsenault Pia R Kamstrup Source Type: research
A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease
In conclusion, these results suggest cilostazol may have beneficial effects in patients with CAD or at a high risk of CV disease.PMID:35743723 | DOI:10.3390/jpm12060938
Source: Atherosclerosis - June 24, 2022 Category: Cardiology Authors: Jia-Ling Lin Wei-Kung Tseng Po-Tseng Lee Cheng-Han Lee Shih-Ya Tseng Po-Wei Chen Hsien-Yuan Chang Ting-Hsing Chao Source Type: research
Impact of sleep apnea and treatments on cardiovascular disease
Sleep Sci. 2022 Apr-Jun;15(2):250-258. doi: 10.5935/1984-0063.20220047.ABSTRACTCardiovascular diseases (CVDs) are the leading causes of mortality worldwide, accounting for nearly 18 million deaths per year. Among other considerations, treating CVDs requires better understanding their risk factors. Sleep-disordered breathing, especially obstructive sleep apnea (OSA), is a likely contributor to several CVDs. We review key epidemiological data that addresses the link between OSA and cardiovascular outcomes such as hypertension, atrial fibrillation (AF), stroke, atherosclerosis, and heart failure (HF), and proposed pathophysio...
Source: Atherosclerosis - June 27, 2022 Category: Cardiology Authors: Andre Faria Arthur Macedo Carolina Castro Elke Valle Raquel Lacerda Najib Ayas Ismail Laher Source Type: research
Risk Factors for Major Adverse Cardiovascular Events and Major Adverse Limb Events after Venous Thromboembolism: A Large Prospective Cohort Study
CONCLUSIONS: Risk factors for MACE and MALE after VTE included some traditional cardiovascular risk factors, patient's comorbidities, and some characteristics of VTE.PMID:35772402 | DOI:10.1055/s-0042-1748152
Source: Atherosclerosis - June 30, 2022 Category: Cardiology Authors: Steve Raoul Noumegni Romain Didier Vincent Mansourati Emmanuelle Le Moigne Raphael Le Mao Cl ément Hoffmann Claire De Moreuil C écile Tromeur Pierre-Yves Le Roux Bahaa Nasr Jean-Christophe Gentric Marie Guegan Elise Poulhazan Karine Lacut Luc Bressollet Source Type: research
Role of Platelet in Parkinson's Disease: Insights into Pathophysiology & amp; Theranostic Solutions
Ageing Res Rev. 2022 Jul 4:101681. doi: 10.1016/j.arr.2022.101681. Online ahead of print.ABSTRACTParkinson's disease (PD) is the second-most-common neurodegenerative disease characterized by motor and non-motor dysfunctions, which currently affects about 10 million people worldwide. Gradual death and progressive loss of dopaminergic neurons in the pars compacta region of substantia nigra results in striatal dopamine deficiency in PD. Specific mutation with further aggregation of α-synuclein in the intraneuronal inclusion bodies is considered the neuropathological hallmark of this disease. PD is often associated with vario...
Source: Atherosclerosis - July 7, 2022 Category: Cardiology Authors: Samir Kumar Beura Abhishek Ramachandra Panigrahi Pooja Yadav Sunil Kumar Singh Source Type: research
NF- κB, A Potential Therapeutic Target in Cardiovascular Diseases
Cardiovasc Drugs Ther. 2022 Jul 7. doi: 10.1007/s10557-022-07362-8. Online ahead of print.ABSTRACTCardiovascular diseases (CVDs) are the leading cause of death globally. Atherosclerosis is the basis of major CVDs - myocardial ischemia, heart failure, and stroke. Among numerous functional molecules, the transcription factor nuclear factor κB (NF-κB) has been linked to downstream target genes involved in atherosclerosis. The activation of the NF-κB family and its downstream target genes in response to environmental and cellular stress, hypoxia, and ischemia initiate different pathological events such as innate and adaptiv...
Source: Atherosclerosis - July 7, 2022 Category: Cardiology Authors: Weijia Cheng Can Cui Gang Liu Chenji Ye Fang Shao Ashim K Bagchi Jawahar L Mehta Xianwei Wang Source Type: research
The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation
Front Cell Infect Microbiol. 2022 Jun 20;12:903570. doi: 10.3389/fcimb.2022.903570. eCollection 2022.ABSTRACTIn the last two decades, considerable interest has been shown in understanding the development of the gut microbiota and its internal and external effects on the intestine, as well as the risk factors for cardiovascular diseases (CVDs) such as metabolic syndrome. The intestinal microbiota plays a pivotal role in human health and disease. Recent studies revealed that the gut microbiota can affect the host body. CVDs are a leading cause of morbidity and mortality, and patients favor death over chronic kidney disease. ...
Source: Atherosclerosis - July 7, 2022 Category: Cardiology Authors: Md Mominur Rahman Fahadul Islam Md Harun -Or-Rashid Abdullah Al Mamun Md Saidur Rahaman Md Mohaimenul Islam Atkia Farzana Khan Meem Popy Rani Sutradhar Saikat Mitra Anjuman Ara Mimi Talha Bin Emran None Fatimawali Rinaldi Idroes Trina Ekawati Tallei Munir Source Type: research
What Is or What Is Not a Risk Factor for Arterial Hypertension? Not Hamlet, but Medical Students Answer That Question
Int J Environ Res Public Health. 2022 Jul 5;19(13):8206. doi: 10.3390/ijerph19138206.ABSTRACTHypertension is a leading cause of cardiovascular disease and premature death worldwide. The most important method of preventing hypertension is social awareness of its causes. An important role in educating society about hypertension is played by medical personnel. The study involved 327 students of medicine representing all years of study. The study used a proprietary questionnaire containing test questions about knowledge of the causes of hypertension (classical and non-classical factors), as well as questionable and false risk ...
Source: Atherosclerosis - July 9, 2022 Category: Cardiology Authors: Tomasz Sobierajski Stanis ław Surma Monika Roma ńczyk Krzysztof Łabuzek Krzysztof J Filipiak Suzanne Oparil Source Type: research
